Rocket Pharmaceuticals, Inc. (RCKT)
Nasdaq: RCKT · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2004
Who owns Rocket Pharmaceuticals, Inc.
As filed with the SECHolders of 5% or more
1
Vanguard Portfolio Management holds 5.35% of Common Stock, as its SCHEDULE 13G filed Jul 31, 2026 says.
Directors and officers
16
report now, of 36 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Vanguard Portfolio Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Maverick Capital, Ltd.
SCHEDULE 13G/A · filed Feb 13, 2026 · Common stock, $0.01 par value per share · reported falling below 5%, from 7.8% in Aug 14, 2025
Wellington Management Group LLP
SCHEDULE 13G/A · filed Jun 5, 2025 · Common Stock · reported falling below 5%, from 6.7% in May 7, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 7.89% in Jan 30, 2026
What RCKT reports owning in othersstakes of 5% or more, and other ties
Rocket Pharmaceuticals, Inc. reports no stake in another company in the record.
Insider tradesForm 4
27sales
1purchases
0sales on a scheduled plan
6people selling
$1.0Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 12, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 39 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Wilson Martin | General Counsel | 9 | $500,000 | 0 | 0 | $0 |
| Shah Gaurav | CEO | 8 | $300,000 | 0 | 0 | $0 |
| Stevens Christopher James | Chief Operating Officer | 1 | $100,000 | 0 | 0 | $0 |
| Chaudhuri Sarbani | See Remarks | 3 | $100,000 | 0 | 0 | $0 |
| Bjork Elisabeth | director | 0 | $0 | 0 | 1 | $0 |
| Militello John | Vice President of Finance, Treasurer, Principal Accounting Officer | 5 | $0 | 0 | 0 | $0 |
| Schwartz Jonathan David | Chief Science & Gene Therapy Officer | 1 | $0 | 0 | 0 | $0 |